Association of Hemoglobin Variability and Mortality among Contemporary Incident Hemodialysis Patients
|
|
- Gabriella Glenn
- 5 years ago
- Views:
Transcription
1 Association of Hemoglobin Variability and Mortality among Contemporary Incident Hemodialysis Patients Steven M. Brunelli,* Katherine E. Lynch,* Elizabeth D. Ankers, Marshall M. Joffe, Wei Yang, Ravi I. Thadhani, and Harold I. Feldman* *Renal-Electrolyte and Hypertension Division, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania; Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania; and Renal Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts Background and objectives: Evidence exists that variability in hemoglobin may be an independent risk factor for mortality among hemodialysis patients. These observations were based on a 1996 cohort, a time when anemia management differed greatly from present. Design, settings, participants and measurements: A retrospective cohort study of patients incident to Fresenius Medical Care units between 2004 and 2005 (n 6644). Hemoglobin variability (Hgb-Var) was defined for each subject as the residual SD of a linear regression model of time on hemoglobin. Results: The mean (SD) of Hgb-Var was 1.13 (0.55) g/dl. In the primary analysis, each g/dl increase of Hgb-Var was associated with an adjusted hazard ratio (95% confidence interval) for all-cause mortality of 1.11 (0.92 to 1.33). No significant interaction with Hgb-Var and mortality was found on the basis of age (P 0.22), arterial disease (P 0.45), Hgb slope (P 0.68), or mean Hgb (P 0.78). When Hgb-Var was defined by a regression model that included a quadratic term for time (enabling descriptions of curvilinear hemoglobin trajectories), model fit was greatly improved (P for difference <0.001). The corresponding adjusted hazard ratio (95% confidence interval) for all-cause mortality was 1.17 (0.93 to 1.49). Conclusions: Hgb-Var was not found to be associated with all-cause mortality when examined in a contemporary incident hemodialysis population. More research is needed to determine whether differences in these findings compared with prior analyses relate to temporal trends in anemia management or from differences in the relationship between Hgb-Var and outcomes among incident versus prevalent hemodialysis patients. Clin J Am Soc Nephrol 3: , doi: /CJN Kidney failure requiring chronic maintenance dialysis is common in the United States, with more than 300,000 people receiving renal replacement therapy in 2005 (1). More than 90% of these patients are treated with erythropoiesis stimulating agents (ESAs) and/or intravenous iron for management of anemia (2). Higher hemoglobin (Hgb) levels in this population result in improved quality of life (3 5) and survival (6 10). Despite more than a decade of research, the optimal anemia management strategy for dialysis patients has yet to be delineated, and guidelines continue to evolve (11). Presently, the Received May 16, Accepted July 30, Published online ahead of print. Publication date available at Work from this study has been submitted to the American Society of Nephrology Meeting, November 2008; a decision regarding acceptance was pending at the time of submission. S.M.B. and K.E.L. contributed equally to this work. Correspondence: Dr. Steven M. Brunelli, Center for Clinical Epidemiology and Biostatistics, 109 Blockley Hall, 423 Guardian Drive, Philadelphia, PA Phone: , Fax: ; steven.brunelli@uphs.upenn.edu National Kidney Foundation Kidney Disease Outcome Quality Initiative recommends targeting Hgb between 11.0 and 12.0 g/dl, but evidence suggests that only 30% of patients fall within this range at any point in time (12), as fluctuations in Hgb levels result in frequent under and overshooting of targets (13 17). Evidence suggests that not only does hemoglobin variability (Hgb-Var) complicate maintenance of Hgb within the target range but that it is also independently associated with mortality (18,19). Previously, we introduced a novel metric (18) (the residual SD about a linear regression of time on observed Hgb values) that characterized Hgb-Var independent of absolute Hgb level and demonstrated an independent association between degree of variability and all-cause mortality among prevalent hemodialysis (HD) patients. However, these findings were based on data from a 1996 cohort whose anemia management was substantially different from more current-day cohorts of patients with end-stage renal disease. Given the dramatic changes in anemia management over the past decade, the applicability of our previous findings needs to be investigated among contemporary dialysis patients. Copyright 2008 by the American Society of Nephrology ISSN: /
2 1734 Clinical Journal of the American Society of Nephrology Clin J Am Soc Nephrol 3: , 2008 Thus, we conducted this retrospective cohort study to examine Hgb-Var and its relation to all-cause mortality using a contemporary cohort of adult HD patients. Materials and Methods Patient Selection We conducted a nonconcurrent cohort study of incident HD patients who enrolled at any Fresenius Medical Care (FMC) unit between June 2, 2004 and August 25, 2005, using the ArMORR cohort (20). To be eligible for inclusion in the primary cohort, patients must have been 18 yr of age or older as of dialysis initiation and have been on HD for a period of less than one month before enrollment. To enable description of Hgb-Var, subjects were required to maintain continuous enrollment in a study unit for at least 180 d. Dialysis sessions missed because of hospitalization, travel, or nonadherence did not constitute violation of continued enrollment; patients recovering renal function, transferring care, changing dialytic modalities, receiving renal transplants, or dying before day 181 were excluded. Ascertainment of Exposures, Outcomes, and Covariates The study data were collected and entered into a centralized database prospectively in a manner previously described (20). No further information was gathered retrospectively. Upon enrollment, patients demographic information and comorbidities were recorded. All laboratory tests were performed in a centralized laboratory (Spectra Laboratories, Rockleigh, NJ), and results were recorded in a central database. At each HD session, detailed records of laboratory tests, medications administered during dialysis (including intravenous iron and erythropoietin), and mortality were collected. Time to death from any cause was the primary outcome. At-risk time began immediately after dialysis day 180 and continued for a maximum of 185 d (at-risk day 185 corresponds to chronic HD day 365). Patients contributed at-risk time until they reached an endpoint (death) or were censored administratively on dialysis day 365 (at-risk day 185), or for change in dialytic modality, transfer of care, recovery of renal function, or receipt of renal transplantation. Hgb was measured regularly (at least monthly) in the course of ongoing dialytic care; Hgbs measured during hospitalization or office visits were not available. To minimize ascertainment bias (e.g., sicker subjects having Hgb measured more frequently), we limited consideration to the first Hgb measure in each month of the observation period; the impact of this choice was explored in sensitivity analyses. These Hgb measurements were used to define each subject s absolute Hgb level (mean of the six values). Hgb-Var and Hgb trend were defined by creation of within-subject linear regression models of time on Hgb. Hgb-Var was considered as the residual SD; Hgb trend was defined as the slope term from these regression models (18). no obvious clinical thresholds exist for Hgb-Var, it was categorized according to observed quartile. In addition, we fit unadjusted and adjusted Cox proportions hazard models to examine the association between Hgb-Var, Hgb slope, and mean Hgb (considered as continuous predictors) and survival. In adjusted models, covariate terms were included for remaining Hgb parameters, demographic, comorbid disease, laboratory, and medication variables. The proportional hazards assumption was tested by inclusion of two-way cross product terms for each Hgb exposure and time. Potential a priori-defined interactions on the bases of Hgb slope, mean Hgb level, arterial disease, and age were explored using two-way cross-product terms in multivariable proportional hazards models and assessed using likelihood ratio testing. Multiple sensitivity analyses were conducted to explore the potential for selection and misclassification biases, including analyses, which included all subjects with definable Hgb-Var (sensitivity analysis I), measured Hgb-Var based on all available Hgb measurements (sensitivity analysis II), and defined Hgb-Var using models that allowed for nonlinear Hgb trajectories (sensitivity analysis III). In each instance, Cox proportional hazards models were specified in an analogous manner to those used in the primary analysis. All analyses were completed using Stata 9.0 (Stata Corporation, College Station, TX). Results Patient Characteristics Among the 10,044 incident HD patients who began treatment at any FMC unit between June 2, 2004 and August 25, 2005, 6644 met criteria for inclusion in the primary cohort (Figure 1). The mean SD age was yr. Table 1 presents demographic, comorbidity, laboratory, and medication characterization of the cohort. Included subjects were significantly younger, had higher body mass indices, were less likely to be white, and were more likely to have hypertension and diabetes than excluded patients. At-risk time began immediately after dialysis day 180. Thus, each subject could contribute a maximum of 185 at-risk days. The cohort contributed an aggregate of 3082 patient-years of Statistical Analysis The distribution of all continuous variables (including Hgb parameters) was examined graphically and via summary statistics; frequency distributions were examined for all categorical variables. The association between pair-wise combinations of Hgb parameters (e.g., Hgb-Var versus mean Hgb) was examined with scatter plots and by calculating Pearson correlation coefficients. The unadjusted association between each Hgb parameter (Hgb-Var, mean Hgb level, and Hgb slope) and all-cause mortality was examined using Kaplan-Meier methods. In these analyses, mean Hgb and Hgb slope were categorized as follows: 11, 11 to 12, 12 to 13, and 13 g/dl, and 0, 0 to 0.5, 0.5 to 1, and 1 g/dl per month, respectively. Because Figure 1. Flow diagram for enrollment.
3 Clin J Am Soc Nephrol 3: , 2008 Hemoglobin Variability and Mortality 1735 Table 1. Characterization of the primary cohort (n 6644) Distribution n Age, years (mean SD) (25th percentile, 51.7; 6644 median, 63.0; 75th percentile, 74.2) Gender male, % female, % Race white, % nonwhite, % BMI, kg/m 2 (mean SD) , % , % , % , % , % Comorbidities, % present diabetes mellitus hypertension arterial disease a coronary artery disease peripheral vascular disease cerebrovascular disease congestive heart failure cancer Laboratory measures (3-month mean SD) b urea reduction ratio, % Kt/V albumin, g/dl bicarbonate, meq/l calcium, mg/dl phosphate, mg/dl creatinine, mg/dl intact PTH, pg/ml Laboratory measures (6-month mean SD) c ferritin, ng/ml transferrin saturation, % Treatment measures c cumulative 6-month intravenous iron dose, mg cumulative 6-month erythropoietin dose, U 559, , average no. of doses per subject average dose per treatment a Arterial disease is not mutually exclusive. b Averaged over dialysis days 91 to 180. c Considered over dialysis days 0 to 180. at-risk time, during which 447 deaths were observed; median follow-up time was 185 d. Hemoglobin Variability Parameters Hemoglobin parameters were defined using monthly Hgb levels over the first 180 study days. Within-subject linear regression models of time on Hgb were used to define Hgb-Var (residual SD) and Hgb trend (slope); in addition, the mean Hgb level for each subject was determined over the same period. The distribution of these parameters is presented in Table 2. Independence of the three Hgb parameters (mean, slope, and variability) was investigated by scatter plot analysis and by calculating Pearson s correlation coefficient for each pairwise combination. The correlation coefficient between Hgb- Var and mean Hgb and Hgb slope were 0.17 and 0.08, respectively; the correlation coefficient between mean Hgb
4 1736 Clinical Journal of the American Society of Nephrology Clin J Am Soc Nephrol 3: , 2008 Table 2. Distribution of hemoglobin variability parameters across the primary cohort (n 6644) Mean SD Quartile 1 Quartile 2 Quartile 3 Quartile 4 Mean Hgb (g/dl) to to to to 15.8 Hgb slope (g/dl per month) to to to to 2.11 Hgb-Var (g/dl) to to to to 4.39 and Hgb slope was In each instance, the low absolute value of the correlation coefficients confirms that these parameters represent independent descriptors of longitudinal Hgb experience. Survival and Hemoglobin Variability Using unadjusted Kaplan Meier analysis, Hgb-Var (considered in quartiles) was not associated with mortality (Figure 2A; P 0.9). Unadjusted and adjusted estimates of association between Hgb-Var and mortality were assessed using Cox proportional hazards models. Considered as a linear term, each g/dl increase in Hgb-Var was associated with an unadjusted and adjusted hazard ratio (HR) (95% confidence interval [CI]) for all-cause mortality of 0.96 (0.81 to 1.14) and 1.11 (0.92 to 1.33), respectively (Table 3). Effect modification of association between Hgb-Var and mortality was explored by the introduction of potential effect modifier cross product terms (e.g., Hgb-Var X age, Hgb-Var X, mean Hgb) into the fully adjusted model and assessed using the likelihood ratio test. No significant interaction on the basis of age (P 0.22), arterial disease (P 0.45), Hgb slope (P 0.68), or mean Hgb (P 0.78) was detected. Sensitivity Analyses Exclusion of subjects missing one or more monthly Hgb levels may have imposed survivor bias, as subjects missing Hgb measurements were likely hospitalized. To explore this possibility, sensitivity analysis I was conducted, which considered all subjects with definable Hgb-Var (i.e., with three or more monthly Hgb levels recorded, n 7474). Unadjusted and adjusted HRs (95% CIs) for all-cause mortality per g/dl increase in Hgb-Var were 0.94 (0.80 to 1.10) and 1.11 (0.92 to 1.33), respectively (Table 4). Because of the possibility that use of only the first Hgb value per month may have introduced bias, sensitivity analysis II was conducted in which Hgb parameters were derived from all available Hgb data for each subject. (The correlation coefficients between these refit Hgb parameters and their counterparts in the primary analysis were 0.96, 0.90, and 0.92 for mean Hgb, Hgb-Var, and Hgb slope, respectively.) Unadjusted and adjusted HRs (95% CIs) for all-cause mortality per g/dl increase in Hgb-Var were 0.99 (0.81 to 1.21) and 1.16 (0.94 to 1.44), respectively (Table 4). For an individual prevalent dialysis patient (in whom little net change in Hgb over time is expected), the trend in Hgb over time was plausibly described by a linear function (18). However, this may not provide the best fit for the data among incident dialysis patients, many of whom are receiving erythropoiesis stimulating therapy for the first time (1). To explore the possibility that nonlinear specification of models provided a better fit of the data, sensitivity analysis III was conducted. In this analysis, quadratic (i.e., time 2 ) and square root terms for time were added (separately) to the within-subject linear regression models used to estimate Hgb-Var and slope. The mean adjusted R 2 was significantly higher for the exposure models that included a quadratic term for time (mean R ) than for those that considered only a linear term (mean R ; P for difference 0.001) or included a square root term (mean R ; P 0.001) in models. When outcome models were fit using Hgb parameters derived from the models including a quadratic term for time, the unadjusted HR (95% CI) per g/dl increase in Hgb-Var was 1.31 (1.05 to 1.64); in the fully adjusted model, the HR (95% CI) was 1.17 (0.93 to 1.49) (Table 4). Survival and Other Hemoglobin Parameters Figure 2B demonstrates that incrementally higher mean Hgb levels were associated with lower all-cause mortality (P 0.001). Considered as a linear term, each g/dl increase in mean Hgb was associated with an unadjusted and adjusted HR (95% CI) for all-cause mortality of 0.72 (0.65 to 0.79) and 0.76 (0.68 to 0.86), respectively (Table 3). The association between mean Hgb level and mortality was quantitatively and qualitatively similar in sensitivity analyses I, II, and III (Table 4). Figure 2C demonstrates that incrementally higher Hgb slopes were associated with lower all-cause mortality (P 0.001). Unadjusted and adjusted HRs (95% CIs) for all-cause mortality per 1 g/dl per month increment in the Hgb slope were 0.66 (0.53 to 0.82) and 0.97 (0.75 to 1.24), respectively (Table 3). The association between Hgb slope and mortality was quantitatively and qualitatively similar in sensitivity analyses I and II (Table 4). Comparison of Data from the 2004 Cohort with 1996 Cohort The differences in findings between those observed in the present cohort and those observed in the 1996 cohort (18) led us to examine differences in the underlying study populations. The 1996 cohort considered both incident and prevalent HD patients, whereas the present cohort included only incident patients. Observed levels of absolute Hgb level (mean 12.0 versus g/dl; P 0.001), Hgb slope (mean 0.37 versus 0.02 g/dl/mo; P 0.001), and Hgb-Var (mean 1.13 versus 0.60, P 0.001) were considerably higher in the present study s cohort than in the full 1996 cohort. When the 1996 cohort was restricted to incident patients and hemoglobin parameters defined over months 0 through 6, the
5 Clin J Am Soc Nephrol 3: , 2008 Hemoglobin Variability and Mortality 1737 A Proportion Surviving B Proportion Surviving C Proportion Surviving Survival by Hgb Var Quartile p > 0.9 Lowest Low High Highest At risk time (days) Survival by Mean Hgb p < <=11 g/dl >11 & <=12 g/dl >12 & <=13 g/dl >13 g/dl At risk time (days) Survival by Hgb Slope p = <=0.0 g/dl/month >0.0 & <=0.5 g/dl/month >0.5 & <=1.0 g/dl/month >1.0 g/dl/month At risk time (days) Figure 2. Survival according to Hgb parameters. (A) Kaplan- Meier survival function for all-cause mortality according to quartile of Hgb-Var. (B) Kaplan-Meier survival function for all-cause mortality according to mean Hgb level ( 11, 11 12, 12 13, 13 g/dl). The number (%) of patients with mean Hgb 11 was 829 (12.5%), mean Hgb 11 to 12 was 2198 (33.1%), mean Hgb 12 to 13 was 2752 (41.4%), and mean Hgb 13 was 865 (13.0%). (C) Kaplan-Meier survival function for all-cause mortality for subjects with Hgb slope 0, 0 to 0.5 g/dl per month, 0.5 to 1 g/dl per month, and 1 g/dl per month. The number (%) of patients with Hgb slope 0 was 1248 (18.8%), Hgb slope 0 to 0.5 was 2936 (44.2%), Hgb slope 0.5 to 1 was 1984 (29.9%), and Hgb slope 1 was 476 (7.2%). association between Hgb-Var and mortality was attenuated and no longer reached conventional levels of statistical significance: adjusted HR (95% CI) 1.15 (0.98 to 1.35). This estimate was similar in magnitude to that seen in the present study, suggesting that the relationship between Hgb-Var and mortality may differ between incident and prevalent HD patients. These findings were changed little when follow-up of these patients was censored on at-risk day 185, the adjusted HR (95% CI) was 1.21 (0.99 to 1.49), suggesting that differences in available follow-up time had little effect on estimates. Recognizing that the 1996 cohort lacked data on many of the covariates included in the present study and incorporated several not used in the present study, we conducted additional analyses to explore the impact of variations in covariate adjustment on our findings. When analyses from the present study were adjusted for only those covariates used in the 1996 study (age, race, sex, diabetes, urea reduction ratio, Kt/V, albumin, bicarbonate, calcium phosphate, parathyroid hormone, ferritin, transferrin saturation, erythropoietin dose and intravenous iron dose, absolute Hgb, Hgb slope), the effect estimate was potentiated and reached conventional levels of statistical significance: adjusted HR (95% CI) was 1.22 (1.01 to 1.48). This suggests that the current analysis may have benefited from more complete adjustment of confounding that was possible for the 1996 analysis. Discussion Previously, we reported an independent and potent association between Hgb-Var and all-cause mortality among a 1996 cohort of prevalent and incident HD patients: each 1 g/dl increase in the residual SD was associated with a 33% increase in mortality (18). Given the dramatic changes in anemia management over the past decade, the present study was undertaken to determine whether this association holds for presentday dialysis patients. Using data from a 2004 to 2005 cohort of incident FMC patients, we were unable to demonstrate an association between Hgb-Var and mortality. At least one other paper has found that Hgb-Var is not associated with mortality (21). That report, as the present study, considered patients from Unlike the present study, that paper considered both incident and prevalent dialysis patients, and used a stratum-based metric of variability, which may not adequately distinguish among variability, per se, absolute hemoglobin level, and temporal hemoglobin trend. To our knowledge, ours was the first report examining the association between Hgb-Var and mortality using a metric that distinguishes variability from these other descriptors of hemoglobin considered longitudinally. There are several potential explanations for observed difference in findings between the present and prior studies. One possibility is that the association between Hgb-Var and mortality is fundamentally different among patients with lower and higher absolute Hgb levels. Both our and published data suggest that absolute Hgb levels were 1 g/dl higher in 2004 than in 1996 (1). Although neither study demonstrated significant effect modification of absolute Hgb level on the association between Hgb-Var and mortality, the range of Hgb level in each
6 1738 Clinical Journal of the American Society of Nephrology Clin J Am Soc Nephrol 3: , 2008 Table 3. Unadjusted and multivariable analyses of Hgb parameters Unadjusted parameters a parameters and demographics b parameters, demographics, and comorbidities c parameters, demographics, comorbidities, amd labs d parameters, demographics, comorbidities, labs, and medications e Hgb-Var (per g/dl) 0.96 ( ) 1.03 ( ) 1.04 ( ) 1.06 ( ) 1.07 ( ) 1.11 ( ) Mean Hgb (per g/dl) 0.72 ( ) 0.73 ( ) 0.69 ( ) 0.70 ( ) 0.78 ( ) 0.76 ( ) Hgb slope (per g/dl 0.66 ( ) 0.71 ( ) 0.83 ( ) 0.86 ( ) 0.93 ( ) 0.97 ( ) per month) a Other variables in the table. b Age, sex, race (white, nonwhite, unknown), BMI ( 20, 20 25, 25 30, 30 35, 35 kg/m 2 ). c Diabetes, hypertension, arterial disease (coronary and/or cerebrovascular and/or peripheral vascular disease), cancer, and congestive heart failure. d Serum creatinine, phosphate, albumin, and ekt/v averaged over days 90 to 180. e Cumulative 6-month intravenous iron and erythropoietin doses. study was constrained (with little overlap between the studies) and may have failed to detect an interaction. An additional possibility is that the association between Hgb- Var and mortality results from differences in anemia treatment over time other than those related to the absolute Hgb level. Between 1996 and 2004, mean erythropoietin dose among HD patients rose from approximately 10,500 to 12,000 units weekly (1). In addition, there was a shift toward use of longer-acting erythropoiesis stimulating agents, as well as subcutaneous versus intravenous administration. Use of intravenous iron increased sharply, and there was a trend away from use of iron dextran formulations in favor of iron sucrose or ferric gluconate (1). Any or all of these secular trends may influence the degree of HgbVar seen and may affect the relationship between Hgb- Var and mortality. Furthermore, it is possible that the effect of Hgb-Var on mortality among incident HD patients differs from that seen among prevalent patients. Indeed, when the 1996 cohort was restricted to only incident HD patients, effect estimates were attenuated and similar to those observed in the present study, suggesting that results differed because of the incident versus prevalent nature of study cohorts. It is unknown whether this derives from a biologic difference or from inadequacy of the Hgb-Var metric when used in incident patients. A difference in the association between Hgb-Var and mortality between incident and prevalent patients is plausible given the known worse health status among incident patients (1). Thus, their overall high mortality rate may diminish the ability to detect a subtler influence of Hgb-Var on longevity. In addition, the effects of Hgb-Var on mortality may take time to manifest and therefore may not be observable in the short time horizon available for the present cohort. When incident subjects from the 1996 cohort were administratively censored on at-risk day 185 (as in the present cohort), the hazard ratio changed very little (though was slightly potentiated), suggesting that insufficient time to manifest sequelae did not attenuate estimates in the present cohort. The observed higher levels of Hgb-Var among the present incident cohort and the incident subgroup of the 1996 cohort, as well as the findings of our sensitivity analysis III, suggest that within-person linear regression to derive Hgb-Var metrics may overstate Hgb-Var among incident patients. It is know that upon HD initiation, a majority of patients ( 60%) receive erythropoiesis stimulating therapy for the first time. These patients experience a robust rise in Hgb early on, followed by a subsequent flattening, leading to a curvilinear trajectory. Use of linear exposure models therefore would misclassify a curved rise in Hgb as variability and create bias. When quadratic exposure models were used to allow for curvilinear relationships, the observed level of Hgb-Var was reduced to 0.68 g/dl, similar to that seen in the 1996 cohort. In addition, when Hgb-Var was defined by these models, there was potentiation of the association between Hgb-Var and mortality. Finally, we cannot rule out the possibility that our current findings differ, in part, from those reported in the 1996 cohort because of greater access to potential confounding factors for the analysis. When the Hgb-Var mortality association was adjusted for those covariates available in the 1996 cohort, the hazard ratio was greater but did not rise to the size observed in the full 1996 cohort (1.22 versus 1.33, respectively). Thus, it is unlikely that residual confounding alone can explain the differences in findings between the two studies. Ultimately, data from a contemporary cohort of prevalent HD population are needed to distinguish whether difference relate to time period effects or to incident versus prevalent status. Unfortunately, such data were not available for the present study. Consistent with published reports (7,10,18,20), our data suggest an association between incrementally higher Hgb and decreased mortality up to a level of 12 g/dl. However, the Kaplan-Meier curves for subjects with mean Hgb 12 to 13 g/dl and 13 g/dl were highly similar, suggesting that further increments in mean Hgb may not be associated with improved survival. The cohort did not contain a sufficient number of subjects with higher mean Hgb levels necessary to draw inference in this regard.
7 Clin J Am Soc Nephrol 3: , 2008 Hemoglobin Variability and Mortality 1739 Table 4. Unadjusted and fully adjusted HRs (95% CIs) for all-cause mortality seen in sensitivity analyses I, II, and III Sensitivity analysis I Sensitivity analysis II Sensitivity analysis III a HgbMs considered First per month All measured First per month No. required HgbMs N HR (95% CI) Unadjusted Fully adjusted b Unadjusted Fully adjusted b Unadjusted Fully adjusted c 1.17 (0.93 to 1.49) 1.31 (1.05 to 1.64) 1.16 (0.94 to 1.44) 0.99 (0.81 to 1.21) 1.11 (0.92 to 1.33) Hgb residual SD (per g/dl) 0.94 (0.80 to 1.10) 0.75 (0.67 to 0.85) 0.72 (0.65 to 0.79) 0.76 (0.67 to 0.85) 0.70 (0.64 to 0.77) 0.76 (0.68 to 0.86) Mean Hgb (per g/dl) 0.67 (0.62 to 0.72) NR NR 0.97 (0.75 to 1.26) 0.70 (0.56 to 0.89) 0.97 (0.77 to 1.24) 0.62 (0.51 to 0.76) Hgb slope (per g/dl per month) HgbMs, hemoglobin measurements; NR, not reported. a In sensitivity analysis III, Hgb parameters were calculated using regression models that included an additional, quadratic term for time. b Covariates included variables, age, sex, race, BMI, comorbidities (diabetes, hypertension, arterial disease (coronary and/or cerebrovascular and/or peripheral vascular disease), cancer, and congestive heart failure), laboratory results (serum creatinine, phosphate, albumin, and ekt/v averaged over days ), and cumulative 6-month intravenous iron and erythropoietin doses. c covariates listed as well as the quadratic representation of hemoglobin over time. In our prior study (18), we demonstrated an association between higher Hgb slope and improved survival. In the present study, this relationship was observed in unadjusted analyses, but not in adjusted analyses, where estimates were greatly attenuated and failed to reach statistical significance. One potential explanation for this discrepancy is that the current study contained data on a greater number of covariates and thus was better able to adjust for the effects of confounding. There are several limitations to this study that must be noted. As with all observational studies, there is the possibility of residual confounding. Although we attempted to adjust estimates, limitations in the available data did not enable us to adjust on the basis of hospitalization, infection, or other potential confounders. It is noteworthy that, when our 1996 data were analyzed using techniques to address time-dependent confounding, the association between Hgb-Var and mortality was potentiated (22). In addition, nonsignificant study findings raise the possibility of a type II error. Although calculations indicated an 80% power to observe a true association (assuming a magnitude similar to that found in the prior study), we cannot discount the possibility that we failed to observe a true association because of a limited number of subjects and limited follow-up time. Finally, all subjects in this study were patients incident to FMC units. Generalization of findings to subjects to prevalent patients or those dialyzed by other providers should be undertaken cautiously. Conclusion The present study was unable to detect an association between Hgb-Var and mortality among incident HD patients. It is unclear whether this lack of association is the result of temporal trends in anemia management or to differences between incident and prevalent dialysis patients. More work is needed to clarify the association between Hgb-Var and mortality before targeting the reduction of Hgb-Var, per se, in clinical practice. Acknowledgments S.M.B. was supported by the American Heart Association Fellow-to- Faculty Transition Award N. Prior work on the 1996 cohort was supported by an unrestricted grant from Hoffman-LaRoche Company. Disclosures None. References 1. U.S. Renal Data System: USRDS 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2007; Accessed October 25, Pisoni RL, Bragg-Gresham JL, Young EW, Akizawa T, Asano Y, Locatelli F, Commer J, Cruz JM, Kerr PG, Mendelssohn DC, Held PJ, Port FK: Anemia management and outcomes from 12 countries in the dialysis outcomes and
8 1740 Clinical Journal of the American Society of Nephrology Clin J Am Soc Nephrol 3: , 2008 practice patterns study (DOPPS). Am J Kidney Dis 44: , Plantinga LC, Fink NE, Jaar BG, Huang I, Wu AW, Meyer KB, Powe NR: Relation between level of changes of hemoglobin and generic and disease-specific quality of life measures in hemodialysis. Qual Life Res 16: , Moreno F, Sanz-Guajardo D, López-Gómez JM, Jofre R, Valderrábano F: Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. J Am Soc Nephrol 11: , McMahon LP, McKenna MJ, Sangkabutra T, Mason K, Sostaric S, Skinner SL, Burge C, Murphy B, Crankshaw D: Physical performance and associated electrolyte changes after haemoglobin normalization: a comparative study in haemodialysis patients. Nephrol Dial Transplant 14: , Robinson BM, Joffe MM, Berns JS, Pisoni RL, Port FK, Feldman HI: Anemia and mortality in hemodialysis patients: accounting for morbidity and treatment variables updated over time. Kidney Int 68: , Portolés J, López-Gómez JM, Aljama P: A prospective multicenter study of the role of anaemia as a risk factor in haemodialysis patients: the MAR Study. Nephrol Dial Transplant 22: , Rao M, Pereira BJ: Optimal anemia management reduces cardiovascular morbidity, mortality, and costs in chronic kidney disease. Kidney Int 68: , Ma JZ, Ebben J, Xia H, Collins AJ: Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 10: , Li S, Collins AJ: Association of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients. Kidney Int 65: , Spiegel DM: Anemia management in chronic kidney disease: what have we learned after 17 years? Semin Dial 19: , National Kidney Foundation: NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: Update 2007, kdoqi/index.com, Accessed October 25, Fishbane S, Berns JS: Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int 68: , Fishbane S, Berns JS: Evidence and implications of haemoglobin cycling in anemia management. Nephrol Dial Transplant 22: , Berns JS, Elzein H, Lynn RI, Fishbane S, Meisels IS, DeOreo PB: Hemoglobin variability in epoetin-treated hemodialysis patients. Kidney Int 64: , West RM, Harris K, Gilthorpe MS, Tolman C, Will EJ: A description of the variability of patient responses in the control of renal anemia: functional data analysis applied to a randomized controlled clinical trial in hemodialysis patients. J Am Soc Nephrol 18: , Ebben JP, Gibertson DT, Foley RN, Collins AJ: Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations. Clin J Am Soc Nephrol 1: , Yang W, Israni RK, Brunelli SM, Joffe MM, Fishbane S, Feldman HI: Hemoglobin variability and mortality in ESRD. J Am Soc Nephrol 18: , Gibertson DT, Ebben JB, Bradbury B, Dunning SC, Collins AJ: The effect of hemoglobin (Hb) variability and trends on mortality. J Am Soc Nephrol 17: 582A, Thadhani R, Tonelli M: Cohort studies: marching forward. Clin J Am Soc Nephrol 1: , Gilbertson DT, Ebben JP, Foley RN, Weinhardl ED, Bradburry BD, Collins AJ: Hemoglbin level variability: associations with mortality. Clin J Am Soc Nephrol 3: , Brunelli SM, Joffe MM, Israni RK, Yang W, Fishbane S, Berns JS, Feldman HI: History-adjusted marginal structural analysis of the association between hemoglobin variability and mortality among chronic hemodialysis patients. Clin J Am Soc Nephrol 3: , 2008 Access to UpToDate on-line is available for additional clinical information at
IN THE LAST few decades, several important
Anemia Management for Hemodialysis Patients: Kidney Disease Outcomes Quality Initiative (K/DOQI) Guidelines and Dialysis Outcomes and Practice Patterns Study (DOPPS) Findings Francesco Locatelli, MD, Ronald
More informationOriginal Article Anemia management trends in patients on peritoneal dialysis in the past 10 years
Int J Clin Exp Med 2015;8(10):18050-18057 www.ijcem.com /ISSN:1940-5901/IJCEM0011104 Original Article Anemia management trends in patients on peritoneal dialysis in the past 10 years Huaye Liu, Yao Yao,
More informationErythropoiesis-stimulating Agents and Anemia in Patients with Non-dialytic Chronic Kidney Disease
ORIGINAL ARTICLE Nephrology http://dx.doi.org/1.3346/jkms.216.31.1.55 J Korean Med Sci 216; 31: 55- Erythropoiesis-stimulating Agents and Anemia in Patients with Non-dialytic Chronic Kidney Disease Sun
More informationMaintenance of target hemoglobin level in stable hemodialysis patients constitutes a theoretical task: a historical prospective study
original article http://www.kidney-international.org & 2008 International Society of Nephrology Maintenance of target hemoglobin level in stable hemodialysis patients constitutes a theoretical task: a
More informationNATIONAL QUALITY FORUM Renal EM Submitted Measures
NATIONAL QUALITY FORUM Renal EM Submitted Measures Measure ID/ Title Measure Description Measure Steward Topic Area #1662 Percentage of patients aged 18 years and older with a diagnosis of CKD ACE/ARB
More informationImprovement in Pittsburgh Symptom Score Index After Initiation of Peritoneal Dialysis
Advances in Peritoneal Dialysis, Vol. 24, 2008 Matthew J. Novak, 1 Heena Sheth, 2 Filitsa H. Bender, 1 Linda Fried, 1,3 Beth Piraino 1 Improvement in Pittsburgh Symptom Score Index After Initiation of
More informationCardiovascular Risk Reduction in Kidney Transplant Recipients
Cardiovascular Risk Reduction in Kidney Transplant Recipients Rainer Oberbauer R.O. AUG 2010 CV Mortality in ESRD compared to the general population R.O.2/32 Modified from Foley et al. AJKD 32 (suppl3):
More informationHemoglobin Variability in Nondialysis Chronic Kidney Disease: Examining the Association with Mortality
Hemoglobin Variability in Nondialysis Chronic Kidney Disease: Examining the Association with Mortality Neil C. Boudville,* Ognjenka Djurdjev, Iain C. Macdougall, Angel L.M. de Francisco, Gilbert Deray,
More informationANEMIA & HEMODIALYSIS
ANEMIA & HEMODIALYSIS The anemia of CKD is, in most patients, normocytic and normochromic, and is due primarily to reduced production of erythropoietin by the kidney and to shortened red cell survival.
More informationOriginal Article. Introduction
Nephrol Dial Transplant (2004) 19: 121 132 DOI: 10.1093/ndt/gfg458 Original Article Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis
More informationPublished trials point to a detrimental relationship
ANEMIA, CHRONIC KIDNEY DISEASE, AND CARDIOVASCULAR DISEASE: THE CLINICAL TRIALS Steven Fishbane, MD* ABSTRACT Clinical trials have shown a strong detrimental relationship among anemia, chronic kidney disease
More informationADVANCES. Annual reports from the Centers for. In Anemia Management. Anemia Management in the United States: Is There Opportunity for Improvement?
ADVANCES Vol. 1 No.1 22 We are pleased to introduce our newest NPA publication, Advances in Anemia Management. This quarterly publication will address contemporary issues relating to the treatment of anemia
More informationVariable Included. Excluded. Included. Excluded
Table S1. Baseline characteristics of patients included in the analysis and those excluded patients because of missing baseline serumj bicarbonate levels, stratified by dialysis modality. Variable HD patients
More informationDavid C. Mendelssohn MD, FRCPC DOPPS Update 2010
David C. Mendelssohn MD, FRCPC DOPPS Update 2010 Budapest Nephrology School August 30, 2010 Overview 1) General aspects of DOPPS 2) Facility based analysis 3) High hemoglobin 4) Coumadin use 5) Summary
More informationChanges in anemia management and hemoglobin levels following revision of a bundling policy to incorporate recombinant human erythropoietin
http://www.kidney-international.org & 11 International Society of Nephrology see commentary on page 265 Changes in anemia management and hemoglobin levels following revision of a bundling policy to incorporate
More informationIntercurrent events and comorbid conditions influence hemoglobin level variability in dialysis patients
Clinical Nephrology, Vol. 71 No. 4/2009 (397-404) Intercurrent events and comorbid conditions influence hemoglobin level variability in dialysis patients Original 2009 Dustri-Verlag Dr. K. Feistle ISSN
More informationSex-specific association of time-varying haemoglobin values with mortality in incident dialysis patients
Nephrol Dial Transplant (2010) 25: 2715 2722 doi: 10.1093/ndt/gfq101 Advance Access publication 26 February 2010 Sex-specific association of time-varying haemoglobin values with mortality in incident dialysis
More informationDefinition and Validation of a Novel Metric of Erythropoiesis-Stimulating Agent Response in Hemodialysis Patients
Special Populations Definition and Validation of a Novel Metric of Erythropoiesis-Stimulating Agent Response in Hemodialysis Patients The Journal of Clinical Pharmacology 2019, 59(3) 418 426 C 2018, The
More informationAJNT. Original Article
. 2012 May;5(2):81-6 Original Article AJNT Reaching Target Hemoglobin Level and Having a Functioning Arteriovenous Fistula Significantly Improve One Year Survival in Twice Weekly Hemodialysis Sarra Elamin
More informationChapter 6: Mortality. Introduction 2016 USRDS ANNUAL DATA REPORT VOLUME 2 ESRD IN THE UNITED STATES
Chapter 6: Mortality In 2014, adjusted mortality rates for ESRD, dialysis, and transplant patients, were 136, 166, and 30, per 1,000 patient-years, respectively. By dialysis modality, mortality rates were
More informationmean hemoglobin 11 g/dl (110 g/l) compared to patients with lower mean hemoglobin values (Table 20).
S44 Figure 53 depicts the trend in Epoetin dosing from the 1998 study period to the 2003 study period, with an increasing mean weekly Epoetin dose (units/kg/wk) for patients prescribed Epoetin in lower
More informationEvidence-based practice in nephrology : Meta-analysis
Evidence-based practice in nephrology : Meta-analysis Paweena Susantitaphong, MD,Ph.D 1-3 1 Associate Professor, Division of Nephrology, Department of Medicine, King Chulalongkorn Memorial Hospital, Chulalongkorn
More informationShorter dialysis times are associated with higher mortality among incident hemodialysis patients
http://www.kidney-international.org & 2010 International Society of Nephrology Shorter dialysis times are associated with higher mortality among incident hemodialysis patients Steven M. Brunelli 1,2, Glenn
More informationHaemodiafiltration - the case against. Prof Peter G Kerr Professor/Director of Nephrology Monash Health
Haemodiafiltration - the case against Prof Peter G Kerr Professor/Director of Nephrology Monash Health Know your opposition.. Haemodiafiltration NB: pre or post-dilution What is HDF how is it different
More informationImpact of Timing of Initiation of Dialysis on Mortality
J Am Soc Nephrol 14: 2305 2312, 2003 Impact of Timing of Initiation of Dialysis on Mortality SRINIVASAN BEDDHU,* MATTHEW H. SAMORE, MARK S. ROBERTS, GREGORY J. STODDARD, NIRUPAMA RAMKUMAR, LISA M. PAPPAS,
More informationA rationale for an individualized haemoglobin target
Nephrol Dial Transplant (2002) 17 [Suppl 6 ]: 2 7 A rationale for an individualized haemoglobin target Norman Muirhead University of Western Ontario, London, Ontario, Canada Abstract Despite the use of
More informationOnce-weekly darbepoetin alfa is as effective as three-times weekly epoetin
Artigo Original ONCE-WEEKLY DARBEPOETIN ALFA IS AS EFFECTIVE AS THREE-TIMES WEEKLY EPOETIN Rev Port Nefrol Hipert 2004; 18 (1): 33-40 Once-weekly darbepoetin alfa is as effective as three-times weekly
More informationIntravenous Iron Requirement in Adult Hemodialysis Patients
Intravenous Iron Requirement in Adult Hemodialysis Patients Timothy V. Nguyen, PharmD The author is a clinical pharmacy specialist with Holy Name Hospital in Teaneck, New Jersey. He is also an adjunct
More informationTitle:Trends in Anemia Management in US Hemodialysis Patients
Author's response to reviews Title:Trends in Anemia Management in US Hemodialysis Patients 2004-2010 Authors: Dana C Miskulin (dmiskulin@tuftsmedicalcenter.org) Jing Zhou (jzhou9@jhmi.edu) Navdeep Tangri
More information( ) , (Donabedian, 1980) We would not choose any treatment with poor outcomes
..., 2013 Amgen. 1 ? ( ), (Donabedian, 1980) We would not choose any treatment with poor outcomes 1. :, 2. ( ): 3. :.,,, 4. :, [Biomarkers Definitions Working Group, 2001]., (William M. Bennet, Nefrol
More informationTransfusion Burden among Patients with Chronic Kidney Disease and Anemia
Transfusion Burden among Patients with Chronic Kidney Disease and Anemia Elizabeth V. Lawler,* Brian D. Bradbury, Jennifer R. Fonda,* J. Michael Gaziano,* and David R. Gagnon* *Massachusetts Veterans Epidemiology
More informationChapter Five Clinical indicators & preventive health
Chapter Five Clinical indicators & preventive health The painter who draws merely by practice and by eye, without any reason, is like a mirror which copies every thing placed in front of it without being
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Serum phosphate GUIDELINES
Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Serum phosphate GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR CLINICAL CARE (Suggestions
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Bucholz EM, Butala NM, Ma S, Normand S-LT, Krumholz HM. Life
More informationHome Hemodialysis or Transplantation of the Treatment of Choice for Elderly?
Home Hemodialysis or Transplantation of the Treatment of Choice for Elderly? Miklos Z Molnar, MD, PhD, FEBTM, FERA, FASN Associate Professor of Medicine Division of Nephrology, Department of Medicine University
More informationCOMPARISON OF THE SURVIVAL OF SHIPPED AND LOCALLY TRANSPLANTED CADAVERIC RENAL ALLOGRAFTS
COMPARISON OF THE SURVIVAL OF SHIPPED AND LOCALLY TRANSPLANTED CADAVERIC RENAL ALLOGRAFTS A COMPARISON OF THE SURVIVAL OF SHIPPED AND LOCALLY TRANSPLANTED CADAVERIC RENAL ALLOGRAFTS KEVIN C. MANGE, M.D.,
More informationAssociation between number of months below K/DOQI haemoglobin target and risk of hospitalization and death
Nephrol Dial Transplant (2008) 23: 1682 1689 doi: 10.1093/ndt/gfm845 Advanced Access publication 8 December 2007 Original Article Association between number of months below K/DOQI haemoglobin target and
More informationComment on European Renal Best Practice Position Statement on Anaemia Management in Chronic Kidney Disease.
Comment on European Renal Best Practice Position Statement on Anaemia Management in Chronic Kidney Disease. Goldsmith D, Blackman A, Gabbay F, June 2013 Kidney Disease: Improving Global Outcomes (KDIGO)
More informationThe Effect of Residual Renal Function at the Initiation of Dialysis on Patient Survival
ORIGINAL ARTICLE DOI: 10.3904/kjim.2009.24.1.55 The Effect of Residual Renal Function at the Initiation of Dialysis on Patient Survival Seoung Gu Kim 1 and Nam Ho Kim 2 Department of Internal Medicine,
More informationSYNOPSIS. Issue Date: 04 February 2009 Document No.: EDMS -USRA
SYNOPSIS Issue Date: 04 February 2009 Document No.: EDMS -USRA-10751204 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Johnson & Johnson Pharmaceutical Research & Development,
More informationImpact of elevated C-reactive protein levels on erythropoiesisstimulating agent (ESA) dose and responsiveness in hemodialysis patients
NDT Advance Access published October 7, 2008 Nephrol Dial Transplant (2008) 1 of 7 doi: 10.1093/ndt/gfn543 Original Article Impact of elevated C-reactive protein levels on erythropoiesisstimulating agent
More informationDialysis Dose and Body Mass Index Are Strongly Associated with Survival in Hemodialysis Patients
J Am Soc Nephrol 13: 1061 1066, 2002 Dialysis Dose and Body Mass Index Are Strongly Associated with Survival in Hemodialysis Patients FRIEDRICH K. PORT, VALARIE B. ASHBY, RAJNISH K. DHINGRA, ERIK C. ROYS,
More informationEvidence Table. Study Type: Randomized controlled trial. Study Aim: To compare frequent nocturnal hemodialysis and conventional in-center dialysis.
Evidence Table Clinical Area: Reference: Frequent home dialysis Culleton BF, Walsh M, Klarenbach SW et al. Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass
More informationLesson #7: Quality Assessment and Performance Improvement
ESRD Update: Transitioning to New ESRD Conditions for Coverage Student Manual Lesson #7: Quality Assessment and Performance Improvement Learning Objectives At the conclusion of this lesson, you will be
More informationMortality for dialysis patients is highest during the
The Right of Passage: Surviving the First Year of Dialysis Rebecca L. Wingard, Kevin E. Chan, J. Michael Lazarus, and Raymond M. Hakim Fresenius Medical Care North America, Waltham, Massachusetts Mortality
More informationpatient characteriuics Chapter Two introduction 58 increasing complexity of the patient population 60 epo use & anemia in the pre-esrd period 62
introduction 58 < increasing complexity of the patient population 6 < epo use & anemia in the pre-esrd period 62 < biochemical & physical characteristics at initiation 64 < estimated gfr at intiation &
More informationPublished trials point to a detrimental relationship
ANEMIA, CHRONIC KIDNEY DISEASE, AND CARDIOVASCULAR DISEASE: THE CLINICAL TRIALS Steven Fishbane, MD* ABSTRACT Clinical trials have shown a strong detrimental relationship among anemia, chronic kidney disease
More informationThe Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009
The Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009 Teresa Northcutt, RN BSN Primaris Program Manager, Prevention - CKD MO-09-01-CKD This material was prepared by Primaris,
More informationThe mortality rate of treated patients with ESRD was 23
Early Intervention Improves Mortality and Hospitalization Rates in Incident Hemodialysis Patients: RightStart Program Rebecca L. Wingard,* Lara B. Pupim, Mahesh Krishnan, Ayumi Shintani, T. Alp Ikizler,
More informationLucia Cea Soriano 1, Saga Johansson 2, Bergur Stefansson 2 and Luis A García Rodríguez 1*
Cea Soriano et al. Cardiovascular Diabetology (2015) 14:38 DOI 10.1186/s12933-015-0204-5 CARDIO VASCULAR DIABETOLOGY ORIGINAL INVESTIGATION Open Access Cardiovascular events and all-cause mortality in
More informationMeeting the Guidelines for End-of-Life Care
Advances in Peritoneal Dialysis, Vol. 22, 2006 Gillian Brunier, David M.J. Naimark, Michelle A. Hladunewich Meeting the Guidelines for End-of-Life Care The number of patients initiating dialysis in most
More informationmorbidity & mortality
morbidity & mortality esrd introduction of ESRD treatment. We examine these concerns throughout the ADR, particularly in Chapter One. This year we focus on infectious complications, especially those related
More informationK atching Up with KDOQI: Clinical Practice Guidelines & Clinical Practice Recommendations for Anemia of Chronic Kidney Disease 2006
K atching Up with KDOQI: Clinical Practice Guidelines & Clinical Practice Recommendations for Anemia of Chronic Kidney Disease 2006 Why new guidelines? Rationale for KDOQI Anemia 2006 Expand scope to all
More informationThe efficacy of intravenous darbepoetin alfa administered once every 2 weeks in chronic kidney disease patients on haemodialysis
Nephrol Dial Transplant (2006) 21: 2846 2850 doi:10.1093/ndt/gfl387 Advance Access publication 5 August 2006 Original Article The efficacy of intravenous darbepoetin alfa administered once every 2 weeks
More informationDialysis outcomes: can we do better?
Dialysis outcomes: can we do better? Allan J. Collins, MD, FACP Professor of Medicine University of Minnesota Director, Chronic Disease Research Group Minneapolis Medical Research Foundation Director,
More informationUC Irvine ICTS Publications
UC Irvine ICTS Publications Title Comparative Mortality-Predictability Using Alkaline Phosphatase and Parathyroid Hormone in Patients on Peritoneal Dialysis and Hemodialysis Permalink https://escholarship.org/uc/item/2732k730
More informationStatus of the CKD and ESRD treatment: Growth, Care, Disparities
Status of the CKD and ESRD treatment: Growth, Care, Disparities United States Renal Data System Coordinating Center An J. Collins, MD FACP Director USRDS Coordinating Center Robert Foley, MB Co-investigator
More informationPublished Online 2013 July 24. Research Article
Nephro-Urology Monthly. 2013 September; 5(4):913-7. Published Online 2013 July 24. DOI: 10.5812/numonthly.12038 Research Article Comparative Study of Intravenous Iron Versus Intravenous Ascorbic Acid for
More informationChronic kidney disease (CKD) has received
Participant Follow-up in the Kidney Early Evaluation Program (KEEP) After Initial Detection Allan J. Collins, MD, FACP, 1,2 Suying Li, PhD, 1 Shu-Cheng Chen, MS, 1 and Joseph A. Vassalotti, MD 3,4 Background:
More informationComparison between short- and long-acting erythropoiesisstimulating agents in hemodialysis patients: target hemoglobin, variability, and outcome
Int Urol Nephrol (2014) 46:453 459 DOI 10.1007/s11255-013-0640-7 NEPHROLOGY - ORIGINAL PAPER Comparison between short- and long-acting erythropoiesisstimulating agents in hemodialysis patients: target
More informationTRENDS IN RENAL REPLACEMENT THERAPY IN BOSNIA AND HERZEGOVINA
& TRENDS IN RENAL REPLACEMENT THERAPY IN BOSNIA AND HERZEGOVINA 2002-2008 Halima Resić* 1, Enisa Mešić 2 1 Clinic for Hemodialysis, University of Sarajevo Clinics Centre, Bolnička 25, 71000 Sarajevo, Bosnia
More informationAssociation of serum sodium and risk of all-cause mortality in patients with chronic kidney disease: A meta-analysis and sysematic review
www.nature.com/scientificreports Received: 19 April 2017 Accepted: 2 November 2017 Published: xx xx xxxx OPEN Association of serum sodium and risk of all-cause mortality in patients with chronic kidney
More informationAranesp. Aranesp (darbepoetin alfa) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.01 Subject: Aranesp Page: 1 of 6 Last Review Date: September 15, 2017 Aranesp Description Aranesp
More informationBecause of important technologic advances achieved over
Anemia and Heart Failure in Chronic Kidney Disease Francesco Locatelli, Pietro Pozzoni, and Lucia Del Vecchio Cardiovascular disease is mainly responsible for the poor long-term survival observed in chronic
More informationPRE-dialysis survey on anaemia management
Nephrol Dial Transplant (2003) 18: 89 100 Original Article PRE-dialysis survey on anaemia management Fernando Valderrábano 1,y, Walter H. Hörl 2, Iain C. Macdougall 3,Jérôme Rossert 4, Boleslaw Rutkowski
More informationSupplementary Online Content
Supplementary Online Content Tangri N, Stevens LA, Griffith J, et al. A predictive model for progression of chronic kidney disease to kidney failure. JAMA. 2011;305(15):1553-1559. eequation. Applying the
More informationRecombinant human erythropoietin (EPO) is an effective
Septicemia in Patients with ESRD Is Associated with Decreased Hematocrit and Increased Use of Erythropoietin Allen R. Nissenson,* Michelle L. Dylan, Robert I. Griffiths, Hsing-Ting Yu, and Robert W. Dubois
More informationTrial to Reduce. Aranesp* Therapy. Cardiovascular Events with
Trial to Reduce Cardiovascular Events with Aranesp* Therapy John J.V. McMurray, Hajime Uno, Petr Jarolim, Akshay S. Desai, Dick de Zeeuw, Kai-Uwe Eckardt, Peter Ivanovich, Andrew S. Levey, Eldrin F. Lewis,
More informationIN-CENTER HEMODIALYSIS (HD) CLINICAL PERFORMANCE MEASURES DATA COLLECTION FORM 2006
IN-CENTER HEMODIALYSIS (HD) CLINICAL PERFORMANCE MEASURES DATA COLLECTION FORM 2006 PATIENT IDENTIFICATION [Before completing please read instructions at the bottom of this page and on pages 5 and 6] MAKE
More information2.0 Synopsis. ABT-358 M Clinical Study Report R&D/06/099. (For National Authority Use Only) to Item of the Submission: Volume:
2.0 Synopsis Abbott Laboratories Name of Study Drug: Zemplar Injection Name of Active Ingredient: Paricalcitol Individual Study Table Referring to Item of the Submission: Volume: Page: (For National Authority
More informationAnemia in ESRD patients is effectively treated by the
Randomized Trial of Model Predictive Control for Improved Anemia Management Michael E. Brier,* Adam E. Gaweda, Andrew Dailey, George R. Aroff, and Alfred A. Jacobs *Department of Veterans Affairs, Louisville,
More informationTitle: Parenteral Iron Therapy for Anemia: A Clinical and Cost-Effectiveness Review
Title: Parenteral Iron Therapy for Anemia: A Clinical and Cost-Effectiveness Review Date: 14 February 2008 Context and policy issues: Anemia is a complication of chronic diseases and commonly occurs in
More informationComparison of mortality with home hemodialysis and center hemodialysis: A national study
Kidney International, Vol. 49 (1996), pp. 1464 1470 Comparison of mortality with home hemodialysis and center hemodialysis: A national study JOHN D. WooDs, FRIEDRICH K. PORT, DAVID STANNARD, CHRISTOPHER
More informationSupplementary Online Content
Supplementary Online Content Swaminathan S, Sommers BD,Thorsness R, Mehrotra R, Lee Y, Trivedi AN. Association of Medicaid expansion with 1-year mortality among patients with end-stage renal disease. JAMA.
More informationClinical Policy: Ferric Carboxymaltose (Injectafer) Reference Number: CP.PHAR.234
Clinical Policy: (Injectafer) Reference Number: CP.PHAR.234 Effective Date: 06/16 Last Review Date: 03/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important
More informationAssociation of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients
Kidney International, Vol. 65 (2004), pp. 626 633 Association of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients SUYING LI and ALLAN J. COLLINS Nephrology
More informationCurrent situation and future of renal anemia treatment. FRANCESCO LOCATELLI
Antalya May 20, 2010 12 National Congress of Turkish Society of Hypertension and Renal Disease Current situation and future of renal anemia treatment. FRANCESCO LOCATELLI Department of Nephrology, Dialysis
More informationNephrology Dialysis Transplantation
Nephrol Dial Transplant (2000) 15 [Suppl 4]: 33 42 Nephrology Dialysis Transplantation European Best Practice Guidelines 9 13 Anaemia management Claude Jacobs, Walter H. Hörl, Iain C. Macdougall, Fernando
More informationComparisons between hemodialysis (HD) and peritoneal
Hemodialysis and Peritoneal Dialysis: Patients Assessment of Their Satisfaction with Therapy and the Impact of the Therapy on Their Lives Erika Juergensen, Diane Wuerth, Susan H. Finkelstein, Peter H.
More informationChapter 5: Acute Kidney Injury
Chapter 5: Acute Kidney Injury Introduction In recent years, acute kidney injury (AKI) has gained increasing recognition as a major risk factor for the development of chronic kidney disease (CKD). The
More informationPOOR LONG-TERM SURVIVAL AFTER ACUTE MYOCARDIAL INFARCTION AMONG PATIENTS ON LONG-TERM DIALYSIS
POOR LONG-TERM SURVIVAL AFTER ACUTE MYOCARDIAL INFARCTION AMONG PATIENTS ON LONG-TERM DIALYSIS CHARLES A. HERZOG, M.D., JENNIE Z. MA, PH.D., AND ALLAN J. COLLINS, M.D. ABSTRACT Background Cardiovascular
More informationFULFILLMENT OF K/DOQI GUIDELINES 92 anemia treatment dialysis therapy vascular access
INTRODUCTION ANEMIA TREATMENT hemoglobin levels epo treatment iron treatment FULFILLMENT OF K/DOQI GUIDELINES 2 anemia treatment dialysis therapy vascular access EPO DOSING PATTERNS 4 epo dosing per kg
More informationNew Aspects to Optimize Epoetin Treatment with Intravenous Iron Therapy in Hemodialysis Patients
23. Berliner DialyseSeminar 1.-4. Dezember 2010 New Aspects to Optimize Epoetin Treatment with Intravenous Iron Therapy in Hemodialysis Patients George R. Aronoff, MD, MS, FACP Professor of Medicine and
More informationEfficacy and tolerability of oral Sucrosomial Iron in CKD patients with anemia. Ioannis Griveas, MD, PhD
Efficacy and tolerability of oral Sucrosomial Iron in CKD patients with anemia Ioannis Griveas, MD, PhD Anaemia is a state in which the quality and/or quantity of circulating red blood cells are below
More informationPERITONEAL DIALYSIS CLINICAL PERFORMANCE MEASURES DATA COLLECTION FORM 2006
PERITONEAL DIALYSIS CLINICAL PERFORMANCE MEASURES DATA COLLECTION FORM 2006 PATIENT IDENTIFICATION [Before completing please read instructions at the bottom of this page and on pages 5 and 6] MAKE CORRECTIONS
More informationComparing Mortality of Peritoneal and Hemodialysis Patients in the First 2 Years of Dialysis Therapy: A Marginal Structural Model Analysis
Article Comparing Mortality of Peritoneal and Hemodialysis Patients in the First 2 Years of Dialysis Therapy: A Marginal Structural Model Analysis Lilia R. Lukowsky,* Rajnish Mehrotra, Leeka Kheifets,
More informationDialysis Adequacy (HD) Guidelines
Dialysis Adequacy (HD) Guidelines Peter Kerr, Convenor (Monash, Victoria) Vlado Perkovic (Camperdown, New South Wales) Jim Petrie (Woolloongabba, Queensland) John Agar (Geelong, Victoria) Alex Disney (Woodville,
More informationGender, low Kt/V, and mortality in Japanese hemodialysis patients: Opportunities for improvement through modifiable practices
Original Articles Gender, low Kt/V, and mortality in Japanese hemodialysis patients: Opportunities for improvement through modifiable practices Naoki KIMATA, 1 Angelo KARABOYAS, 2 Brian A. BIEBER, 2 Ronald
More informationHematocrit Level and Associated Mortality in Hemodialysis Patients
J Am Soc Nephrol 10: 610 619, 1999 Hematocrit Level and Associated Mortality in Hemodialysis Patients JENNIE Z. MA,* JIM EBBEN, HONG XIA, and ALLAN J. COLLINS* *Division of Nephrology, Hennepin County
More informationORIGINAL RESEARCH. 224 Journal of Renal Nutrition, Vol 20, No 4 (July), 2010: pp
ORIGINAL RESEARCH Independent and Joint Associations of Nutritional Status Indicators With Mortality Risk Among Chronic Hemodialysis Patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS)
More informationGSK Medicine: Study Number: Title: Rationale: Study Period: Objectives: Indication: Study Investigators/Centers: Research Methods: Data Source
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationClinical Policy: Ferumoxytol (Feraheme) Reference Number: CP.PHAR.165
Clinical Policy: (Feraheme) Reference Number: CP.PHAR.165 Effective Date: 03/16 Last Review Date: 03/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationAnemia management in ESRD patients is a matter of
Determining Optimum Hemoglobin Sampling for Anemia Management from Every-Treatment Data Adam E. Gaweda,* Brian H. Nathanson, Alfred A. Jacobs,* George R. Aronoff,* Michael J. Germain, and Michael E. Brier*
More informationIndividual Study Table Referring to Part of Dossier: Volume: Page:
Synopsis Abbott Laboratories Name of Study Drug: Paricalcitol Capsules (ABT-358) (Zemplar ) Name of Active Ingredient: Paricalcitol Individual Study Table Referring to Part of Dossier: Volume: Page: (For
More informationThe Changing Clinical Landscape of Anemia Management in Patients With CKD: An Update From San Diego Presentation 1
Presentation 1 The following is a transcript from a web-based CME-certified multimedia activity. Interactivity applies only when viewing the activity online. This activity is supported by educational grants
More informationInternational Journal of Current Research in Chemistry and Pharmaceutical Sciences Volume 1 Issue: Pages: 20-28
International Journal of Current Research in Chemistry and Pharmaceutical Sciences www.ijcrcps.com Volume 1 Issue: 3 2014 Pages: 20-28 (p-issn: 2348-5213; e-issn: 2348-5221) REVIEW ARTICLE PREVALENCE OF
More informationImproved survival of type 2 diabetic patients on renal replacement therapy in Finland
Nephrol Dial Transplant (2010) 25: 892 896 doi: 10.1093/ndt/gfp555 Advance Access publication 21 October 2009 Improved survival of type 2 diabetic patients on renal replacement therapy in Finland Marjo
More informationClinical Policy: Iron Sucrose (Venofer) Reference Number: CP.PHAR.167
Clinical Policy: (Venofer) Reference Number: CP.PHAR.167 Effective Date: 03/16 Last Review Date: 03/17 Revision Log Coding Implications See Important Reminder at the end of this policy for important regulatory
More informationNo Disclosures 03/20/2019. Learning Objectives. Renal Anemia: The Basics
Renal Anemia: The Basics Meredith Atkinson, M.D., M.H.S. Associate Professor of Pediatrics Johns Hopkins School of Medicine 16 March 2019 No Disclosures Learning Objectives At the end of this session the
More informationRegional variability in anaemia management and haemoglobin in the US
Nephrol Dial Transplant (2003) 18: 147 152 Original Article Regional variability in anaemia management and haemoglobin in the US Donal N. Reddan 1, Diane L. Frankenfield 2, Preston S. Klassen 1, Joseph
More information